HoldsUp

Robin Carhart-Harris

Robin Carhart-Harris is a neuroscientist specializing in psychedelic research and psychedelic psychiatry. His research investigates the neurobiological mechanisms and clinical applications of substances such as psilocybin, LSD, MDMA, DMT, and ketamine. His published work focuses on their therapeutic potential for conditions like major depressive disorder, as well as their effects on brain connectivity, neuroplasticity, and subjective experience.

25 claims checked on air: 1 contradicted 2 overstated 18 supported 4 unverified

What they said on air - citing their own research

2 citing their own research

0:19:00supportedmoderatetheir own paperWhy Your Brain is Stuck: The Truth About Psychedelics and Pl

Psychedelics do not shut down the default mode network, but rather cause dysregulation and irregular activity patterns within it.

"it's not that we shut off the default mode network. That's a popular in a sense myth that people like and you can get away with it, but it's not really true. You're not turning it off, you're scrambling it up. And in scrambling it up—and I say it that way because it's still very active, it's just the activity is irregular now." (said at 0:19:00)

Human neuroimaging studies confirm that psychedelics do not deactivate or 'shut off' the default mode network (DMN). Instead, acute administration of serotonergic psychedelics such as psilocybin disrupts the coordinated functional connectivity and synchronization within the DMN and between large-scale networks—characterized by reduced internal network integrity, desynchronization, and increased entropy/irregularity of activity patterns.

0:26:54supportedmoderatetheir own paperWhy Your Brain is Stuck: The Truth About Psychedelics and Pl

Emotional release during psychedelic sessions is a key factor predicting positive clinical outcomes.

"The other one is emotional release. It's strong emotion. What What is that? What's that look like? Well, often it looks like people crying... it's a cathartic a cathartic release." (said at 0:26:54)

Clinical and prospective studies consistently show that experiencing an emotional breakthrough or emotional release (commonly measured by the Emotional Breakthrough Inventory, or EBI) during psychedelic administration is a robust predictor of subsequent clinical improvement. In a Phase II randomized trial of psilocybin for treatment-resistant depression, EBI scores had one of the strongest correlations (r = -0.637) with reductions in depression severity at 3 weeks post-treatment. Similar predictive relationships between emotional breakthrough and improvements in mental well-being and depressive symptoms have been replicated across observational and clinical datasets.

Fact-checked episodes

Publications